ClinicalTrials.gg
RecruitingNCT04187820Updated May 14, 2025

Effect of Acupuncture on Mild to Moderate Active Crohn's Disease

An interventional study of acupuncture in Intestinal Disorder, Inflammatory Bowel Diseases and Crohn Disease, sponsored by Shanghai Institute of Acupuncture, Moxibustion and Meridian. Recruiting at 2 sites in China. Open to participants aged 16 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-14.

Primary conditionCrohn DiseaseRegistry: Intestinal DiseasesReclassifiedWhy we changed it
Registry
Intestinal Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Crohn Disease
Why
  1. The study's listed conditions name Crohn Disease, a narrower term within Intestinal Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Shanghai Institute of Acupuncture, Moxibustion and Meridian · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jun 2019, registered Dec 2019).
  • Started Jun 2019; still recruiting 7 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
16 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 192 studies in Crohn Disease with a site in China — 75 open to participants now, 88 under way, 22 of them phase 3. Crohn Disease · China.

Planned enrollment
92nd of 129
60 · median 110
Started
2019
with 7 others
No phase
49 of 192
20 open now
Primary completion
2026-12
later than 32 of 87 live
Registered
57th of 192
by date
Lead sponsor
8 of 192
Shanghai Institute of Acupuncture, Moxibustion and Meridian

Among the 192 studies in Crohn Disease with a site in China, this one is the 92nd largest by planned enrollment of the 129 interventional ones that give a count, is one of 8 that started in 2019, is one of 49 with no phase, reaches primary completion later than 32 of the 87 other live ones, and was the 57th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

75 of the 192 studies in Crohn Disease with a site in China are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 16 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 192 studies in Crohn Disease with a site in China, or all of them as a file.
02

Study summary

To observe the clinical effect of acupuncture on Crohn's disease (CD) and its influence on brain function activity and the TRY-KYN metabolism level, and to screen the brain image markers of acupuncture on CD

Read the detailed description
  1. Effect of acupuncture on symptoms of CD
  2. Effect of acupuncture on brain functional activity of CD
  3. Effect of acupuncture on intestinal and plasma TRP-KYN metabolism level of CD
  4. Screen the brain image markers of acupuncture in the treatment of CD
03

Conditions studied

  • Intestinal Disorder
  • Inflammatory Bowel Diseases
  • Crohn Disease

Browse trials for

Keywords

  • acupuncture
  • Crohn's disease
04

In context

Crohn Disease Reclassified

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

This study's planned enrollment of 60 is below the median of 67 across 1,262 interventional studies indexed under Crohn Disease.

Browse Crohn Disease studies →

Lead sponsor

Shanghai Institute of Acupuncture, Moxibustion and Meridian is the lead sponsor of 29 studies on the registry; 5 are open to participants now.

Compared within Crohn Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Intestinal Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
16 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. aged 16-70;
  2. patients with mild or moderate active disease (150 ≤ CDAI \< 450);
  3. patients who are not responsive, intolerant, dependent or refused to use at least mesalazine, , immunomodulator (azathioprine, methotrexate), anti TNF alpha preparation;
  4. patients were not taking medication or were only taking one or more of the following drugs: [prednisone ≤15mg/d, azathioprine (≤1mg/kg/d), methotrexate (≤15mg/w) or mesalazine (≤4g/d)] and prednisone was used for at least 1 month, while azathioprine, methotrexate or mesalazine was used for at least 3 months;
  5. those who did not use anti-TNF alpha and other agents within 3 months before entering the study;
  6. those who have never experienced acupuncture;
  7. patients signing .

Exclusion criteria

Exclusion Criteria:

  1. patients who are recently pregnant or in pregnancy or lactation;
  2. patients with serious organic diseases;
  3. patients diagnosed as psychosis;
  4. patients who take antibiotics, probiotics, traditional Chinese medicine and other drugs at the same time, or who suffer from multiple diseases and need to take other drugs for a long time, and may affect the observation of the efficacy of this trial;
  5. severe skin diseases (such as erythema nodosum, pyoderma gangrenosum, etc.), eye diseases (such as iritis, uveitis, etc.), thromboembolic diseases and other serious extraintestinal manifestations;
  6. there are serious intestinal fistula, abdominal abscess, intestinal stenosis and obstruction, perianal abscess, gastrointestinal hemorrhage, intestinal perforation and other complications;
  7. patients with short bowel syndrome who have undergone abdominal or gastrointestinal surgery in the past half a year;
  8. there are skin diseases or defects in the selected area of acupuncture and moxibustion that cannot be performed.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Acupuncture group

    Participants receiving acupuncture and mild moxibustion.

    Other: acupuncture

Interventions

  • Otheracupuncture

    Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. In the acupuncture group, Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustIon.

07

What researchers measure

Primary outcomes

  1. Clinical remission

    Crohn's disease activity index (CDAI)less than 150 and decreased more than 70

    Time frame: Week 12

Secondary outcomes

  1. Clinical remission

    Crohn's disease activity index (CDAI) less than 150 and decreased more than 70

    Time frame: Week 24, 36 and 48

  2. Clinical response

    Crohn's disease activity index (CDAI) decreased more than 70

    Time frame: Week 12, 24, 36 and 48

  3. Crohn's disease activity index (CDAI)score

    The mean change in CDAI from baseline. The higher the score, the worse the condition. Greater than 0, no upper limit.

    Time frame: Week 12, 24, 36 and 48

  4. laboratory test

    serum C-reactive protein (CRP) level

    Time frame: Week 12, 24, 36 and 48

  5. laboratory test

    Erythrocyte sedimentation rate (ESR)

    Time frame: Week 12, 24, 36 and 48

  6. laboratory test

    Platelet count

    Time frame: Week 12, 24, 36 and 48

  7. Inflammatory bowel disease questionnaire (IBDQ)

    The mean change in IBDQ from baseline. The higher the score, the worse the condition.The score is range from 32 to 224.

    Time frame: Week 12 and 24

  8. Crohn's disease endoscopic index of severity (CDEIS)

    The mean change in CDEIS from baseline

    Time frame: Week 48

  9. Hospital anxiety and depression scale (HADS)

    The mean change in HADS from baseline. The higher the score, the more serious the disease. The depression and anxiety score is range from 0 to 21.

    Time frame: Week 12 and 24

  10. The proportion of recurrences

    Defined as CDAI \> 150 and increase ≥ 70 points or need to adjust drug to control disease condition.

    Time frame: Week 48

  11. Brain functional and structural changes

    measured by functional MRI

    Time frame: Week 12

  12. Plasma and intestinal TRP-KYN metabolism level

    Plasma and intestinal Indoleamine2,3dioxygenase 1 (IDO1)level

    Time frame: Week 12

  13. Plasma and intestinal TRP-KYN metabolism level

    Plasma and intestinal Tryptophan (TRP) level

    Time frame: Week 12

  14. Plasma and intestinal TRP-KYN metabolism level

    Plasma and intestinal kynurenine (KYN)level

    Time frame: Week 12

  15. Plasma and intestinal TRP-KYN metabolism level

    Plasma and intestinal kynurenic acid (KYNA) level

    Time frame: Week 12

  16. Plasma and intestinal TRP-KYN metabolism level

    Plasma and intestinal quinolinic acid (QUIN) level

    Time frame: Week 12

  17. Plasma and intestinal TRP-KYN metabolism level

    Plasma and intestinal IFN-gamma level

    Time frame: Week 12

  18. Plasma and intestinal TRP-KYN metabolism level

    Plasma and intestinal IL-1beta level

    Time frame: Week 12

  19. Plasma and intestinal TRP-KYN metabolism level

    Plasma and intestinal IL-18 level

    Time frame: Week 12

Other outcomes

  1. Analysis of intestinal microbes

    Application of 16S sequencing to analyze the gut microbial composition, structure and diversity of patients.

    Time frame: Week 12

  2. Analysis of the association between gut microbes, brain imaging and behavior

    The pearson correlation and linear regression models were applied to establish the association between gut microbes, brain function and structure and behavior in an attempt to explore the relationship between the gut microbe-gut-brain axis in patients with active CD.

    Time frame: Week 12

  3. Acupuncture efficacy prediction

    Deep learning algorithms such as artificial neural networks and support vector machines were applied to construct and validate an acupuncture efficacy prediction model based on MRI changes in high and low response patients in the acupuncture group, and to screen brain neuroimaging markers that predict the effective relief of CD disease activity by acupuncture.

    Time frame: Week 48

  4. Disease activity prediction

    Differences in brain structure and functional activity between active CD patients and remitting CD patients as well as healthy subjects are measured, and deep learning algorithms such as artificial neural networks and support vector machines are applied to construct and validate disease diagnostic models and screen brain imaging markers that predict CD disease activity.

    Time frame: Week 0

08

Study locations

2 of 2 sites recruiting
  • Shanghai Research Institute of Acupuncture and Meridian
    Shanghai, Shanghai 200030, China
    Recruiting
    • Chunhui Bao, Doctor · Contactbaochunhui789@126.com · +862164395973
    • Huangan Wu, Doctor · Principal investigator
  • Guona Li
    Shanghai, 2000, China
    Recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2019 (actual). Primary completion is estimated for Dec 2026, 90 months after the start.

Of 290 non-industry interventional studies with no phase under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 90 months is above that.

Counting every sponsor, half of 302 studies reached it within 45 months; a quarter within 21 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2019
First posted
Dec 5, 2019
StartActual
Jun 1, 2019
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04187820
Lead sponsor
Shanghai Institute of Acupuncture, Moxibustion and Meridian
Responsible party
Sponsor
First posted
Dec 5, 2019
Start date
Jun 1, 2019
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 14, 2025

Study contacts

Chunhui Bao, MD, PhD
Contact
baochunhui789@126.com
+862164395973
Huangan Wu, MD, PhD
study chair · Shanghai Research Institute of Acupuncture and Meridian

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion